Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cytomedix (OTC: CMXI) CMS Approval Of Clinical Outcomes For AutoloGel

The AutoloGel System is a point-of-care system for exuding wounds: leg ulcers, pressure ulcers and diabetic ulcers

The Center for Medicare & Medicaid Services (NYSE:CMS) has granted formal approval of the clinical outcomes defined in 4 protocols in response to the National Coverage Determination (NCD) memo for autologous blood derived products for chronic wound care issued last August by CMS.

The Bottom Line: With these protocol approvals, clinicians can use AutoloGel(NYSE:TM) to treat Medicare beneficiaries with chronic wounds and receive reimbursement for the product under the Coverage with Evidence Development (CED) program. CMXI expects to begin rolling out the protocols to wound care clinics during March, and anticipates the first patients will be treated under the protocols soon.

CMXI closed at $0.50 on 3/1/13. Ranked a "BUY" as it appears Osiris' Grafix also targets diabetic ulcers, it appears to have direct overlap with CMXI 's AutoloGel < it also has unconditional CMS coverage>. However, under the approved protocols, CMXI … expects to treat more than 1,200 patients with AutoloGel in outpatient wound care centers affiliated with Intellicure and the US Wound Registry while OSIR has to develop a sales and marketing group to advance.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.